Bemiparin is a LMWH obtained by depolymerization of heparin from porcine intestinal mucosa. Bemiparin has confirmed its antithrombotic activity and, at the recommended doses, it does not significantly prolong global clotting tests.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| B01AB12 | Bemiparin | B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AB Heparin group |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| ZIBOR 25.000 IU Solution for injection | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| ZIBOR 3.500 IU Solution for injection | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| ZIBOR 2.500 IU Solution for injection | MPI, EU: SmPC | Health Products Regulatory Authority (IE) |
Bemiparin is an active ingredient of these brands:
Austria (AT)Estonia (EE)
Hong Kong (HK)
Ireland (IE)
Lithuania (LT)Poland (PL)
Romania (RO)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.